Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
4D Molecular Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
FDMT
Nasdaq
8731
https://4dmoleculartherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for 4D Molecular Therapeutics Inc
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
- Mar 28th, 2024 12:00 pm
4DMT to Participate in Upcoming Investor Conferences
- Mar 4th, 2024 1:00 pm
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
- Mar 3rd, 2024 2:03 pm
4D Molecular Therapeutics Full Year 2023 Earnings: Misses Expectations
- Mar 2nd, 2024 1:55 pm
4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results
- Mar 2nd, 2024 9:32 am
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates
- Feb 29th, 2024 11:05 pm
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
- Feb 29th, 2024 9:05 pm
Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
- Feb 26th, 2024 8:58 am
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposiumâ„¢ 2024
- Feb 12th, 2024 1:00 pm
Institutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growth
- Feb 12th, 2024 12:48 pm
Chief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics Inc
- Feb 8th, 2024 8:05 am
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
- Feb 7th, 2024 4:27 am
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
- Feb 5th, 2024 9:05 pm
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'
- Feb 5th, 2024 5:36 pm
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
- Feb 3rd, 2024 10:00 pm
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
- Jan 29th, 2024 1:00 pm
4D Molecular Therapeutics Inc CEO David Kirn Sells 5,696 Shares
- Jan 26th, 2024 3:04 am
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
- Jan 23rd, 2024 1:00 pm
All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy
- Jan 19th, 2024 5:00 pm
4D Molecular Therapeutics Inc CEO David Kirn Sells 102,303 Shares
- Jan 9th, 2024 10:02 am
Scroll